Author/Authors :
Arman T. Askari، نويسنده , , Samuel Unzek، نويسنده , , Zoran B. Popovic?، نويسنده , , Corey K. Goldman، نويسنده , , Farhad Forudi، نويسنده , , Matthew Kiedrowski، نويسنده , , Aleksandr Rovner، نويسنده , , Stephen G Ellis، نويسنده , , James D Thomas، نويسنده , , Paul E. DiCorleto، نويسنده , , Eric J Topol، نويسنده , , Marc S. Penn، نويسنده ,
Abstract :
Background
Myocardial regeneration via stem-cell mobilisation at the time of myocardial infarction is known to occur, although the mechanism for stem-cell homing to infarcted tissue subsequently and whether this approach can be used for treatment of ischaemic cardiomyopathy are unknown. We investigated these issues in a Lewis rat model (ligation of the left anterior descending artery) of ischaemic cardiomyopathy.
Methods
We studied the effects of stem-cell mobilisation by use of granulocyte colony-stimulating factor (filgrastim) with or without transplantation of syngeneic cells. Shortening fraction and myocardial strain by tissue doppler imaging were quantified by echocardiography.
Findings
Stem-cell mobilisation with filgrastim alone did not lead to engraftment of bone-marrow-derived cells. Stromal-cell-derived factor 1 (SDF-1), required for stem-cell homing to bone marrow, was upregulated immediately after myocardial infarction and downregulated within 7 days. 8 weeks after myocardial infarction, transplantation into the peri-infarct zone of syngeneic cardiac fibroblasts stably transfected to express SDF-1 induced homing of CD117-positive stem cells to injured myocardium after filgrastim administration (control vs SDF-1-expressing cardiac fibroblasts mean 7•2 [SD 3•4] vs 33•2 [6•0] cells/mm2, n=4 per group, p<0•02) resulting in greater left-ventricular mass (1•24 [0•29] vs 1•57 [0•27] g) and better cardiac function (shortening fraction 9•2 [4•9] vs 17•2 [4•2]%, n=8 per group, p<0•05).
Interpretation
These findings show that SDF-1 is sufficient to induce therapeutic stem-cell homing to injured myocardium and suggest a strategy for directed stem-cell engraftment into injured tissues. Our findings also indicate that therapeutic strategies focused on stem-cell mobilisation for regeneration of myocardial tissue must be initiated within days of myocardial infarction unless signalling for stem-cell homing is reestablished.
